Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine.

Although the primary endpoint of proteinuria reduction did not reach statistical significance, a trend toward decreased proteinuria over 12 months was observed, suggesting potential clinical benefit in subsets of patients with higher complement activation.

also in 111,027 other papers